ArticleJornal brasileiro de nefrologia
Troponin I is an independent marker of cardiovascular mortality risk in chronic kidney disease patients.
Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiovascular disease (CVD) is the main cause of death among chronic kidney disease (CKD) patients. However, the cardiovascular (CV) prognostic evaluation in CKD is not established. Despite previous reports establishing troponin as a CV mortality prognosticator in CKD, there is no consensus on its applicability. Moreover, studies on high-sensitivity troponin I (hsTnI) in this context are scarce. We evaluated the association between hsTnI and CV and overall mortality among CKD patients to identify higher CV-risk patients.
methods145 patients with CKD stages 3 to 5 underwent measurements of hsTnI, inflammatory, calcium-phosphorus metabolism, vascular calcification, and echocardiographic parameters. The association of hsTnI with CV and overall mortality after follow-up was established using Kaplan-Meier curves. The cutoff value of hsTnI for predicting CV and overall mortality was defined using ROC curve analysis. Multivariate analysis for CV and overall mortality was done using Cox regression models.
resultsHsTnI cutoff value for overall and CV mortality was 0.057 ng/mL. Patients with higher hsTnI had higher CV and overall mortality. In multivariate analysis, hsTnI was a marker of increased CV mortality (hazard ratio 12.8 (95% CI 1.56-105.08), p = 0.018), independent of age, sex, previous CVD, diabetes and dialysis, echocardiographic findings, and osteo-protegerin (OPG).
conclusionHsTnI is independently associated with CV mortality in CKD patients, suggesting that it may be a potential CV risk stratification marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.